Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2%

NCT02031445 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

73

Enrollment

INDUSTRY

Sponsor class

Stopped Interim analysis showed lack of efficacy

Conditions

Atopic Dermatitis

Interventions

DRUG: MRX-6
OTHER: Placebo

Sponsor

Celsus Therapeutics PLC